Skip to main content

Table 4 Risk of second primary cancer after primary POFT cancer diagnosis according to stage*

From: Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study

Stage Localized Regional Distant
SIR CI SIR CI SIR CI
Leukaemia 2.73 (0.33–9.87) 1.96 (0.05–10.92) 4.94# (1.60–11.53)
Urinary bladder 0.00 (0.00–8.53) 0.00 (0.00–11.82) 4.51 (0.93–13.18)
Lung, bronchus 3.46# (1.94–5.71) 0.61 (0.07–2.22) 0.88 (0.32–1.92)
Rectum, rectosigmoid junction 1.89 (0.69–4.11) 0.85 (0.10–3.06) 2.28# (1.14–4.08)
Thyroid 2.38# (1.79–3.10) 1.32 (0.80–2.03) 1.19 (0.82–1.67)
Colon 2.10# (1.20–3.41) 1.58 (0.72–2.99) 1.36 (0.78–2.21)
Ascending colon 2.87 (0.78–7.34) 1.88 (0.23–6.79) 0.45 (0.01–2.48)
Transverse colon 1.72 (0.04–9.56) 0.00 (0.00–8.36) 0.00 (0.00–3.98)
Descending colon 1.94 (0.53–4.97) 1.94 (0.40–5.67) 0.63 (0.08–2.29)
Rectum 1.88 (0.69–4.10) 0.84 (0.10–3.05) 2.27# (1.13–4.06)
Other and unspecified 2.52 (0.06–14.05) 7.03 (0.85–25.38) 3.34 (0.40–12.05)
Female breast 0.99 (0.53–1.69) 1.56 (0.85–2.62) 1.27 (0.79–1.94)
Kidney parenchyma 2.19 (0.27–7.92) 0.00 (0.00–5.45) 2.21 (0.46–6.45)
Renal pelvis, other urinary 0.00 (0.00–18.45) 0.00 (0.00–24.4) 9.17# (1.89–26.8)
Pancreas 2.66 (0.73–6.82) 0.89 (0.02–4.95) 0.00 (0.00–1.54)
Non-Hodgkin lymphoma 1.49 (0.18–5.39) 0.00 (0.00–3.79) 0.52 (0.01–2.87)
Bile ducts, other biliary 1.89 (0.39–5.52) 0.00 (0.00–3.11) 3.12# (1.35–6.14)
Stomach 0.29 (0.04–1.05) 0.99 (0.32–2.31) 0.48 (0.16–1.12)
Liver 1.02 (0.12–3.69) 0.66 (0.02–3.69) 0.63 (0.08–2.29)
Gallbladder 1.24 (0.03–6.93) 1.68 (0.04–9.39) 0.00 (0.00–2.90)
Small intestine 0.00 (0.00–18.16) 6.62 (0.17–36.87) 0.00 (0.00–11.87)
All excluding POFT 1.72# (1.44–2.05) 1.16 (0.89–1.50) 1.28# (1.07–1.52)
  1. *Stage data was used since 2006
  2. POFT: peritoneal, epithelial ovarian, and fallopian tubal; SIR: standardised incidence ratio; CI: confidence interval
  3. #significant at α = 0.05